EGFR and non-small cell lung carcinoma: Moving forward, a phase III, randomized trial (MARIPOSA) is designed to compare the combination of amivantamab and lazertinib to osimertinib monotherapy as the first-line treatment for EGFR-mutant NSCLC [16].